{"id":"https://openalex.org/W2002180296","doi":"https://doi.org/10.3109/j058v17n03_03","title":"Sales of Brand-Name Products and Generic Competitors Before and After Market Entry of Product Line Extensions in Canada","display_name":"Sales of Brand-Name Products and Generic Competitors Before and After Market Entry of Product Line Extensions in Canada","publication_year":2006,"publication_date":"2006-01-01","ids":{"openalex":"https://openalex.org/W2002180296","doi":"https://doi.org/10.3109/j058v17n03_03","mag":"2002180296"},"language":"en","primary_location":{"id":"doi:10.3109/j058v17n03_03","doi":"https://doi.org/10.3109/j058v17n03_03","is_oa":false,"landing_page_url":"https://doi.org/10.3109/j058v17n03_03","pdf_url":null,"source":{"id":"https://openalex.org/S9455094","display_name":"Journal of Pharmaceutical Marketing & Management","issn_l":"0883-7597","issn":["0883-7597","1540-8574"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320623","host_organization_name":"Haworth Press","host_organization_lineage":["https://openalex.org/P4310320623"],"host_organization_lineage_names":["Haworth Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical Marketing & Management","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102093473","display_name":"Hui Yi Xue","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Hui Yi Xue","raw_affiliation_strings":["Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada","institution_ids":["https://openalex.org/I185261750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065436197","display_name":"Ho Lun Wong","orcid":"https://orcid.org/0000-0001-5516-3497","observed_orcids":["https://orcid.org/0000-0001-5516-3497"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Ho Lun Wong","raw_affiliation_strings":["Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada","institution_ids":["https://openalex.org/I185261750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102093474","display_name":"Patrick Wong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I144743875","display_name":"Vocational Training Council","ror":"https://ror.org/02pvbz391","country_code":"HK","type":"government","lineage":["https://openalex.org/I144743875"]}],"countries":["HK"],"is_corresponding":false,"raw_author_name":"Patrick Wong","raw_affiliation_strings":["School of Business and Information Systems, Vocational Training Council, 20A Tsing Yi Road, Tsing Yi Island, N.T., Hong Kong"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Business and Information Systems, Vocational Training Council, 20A Tsing Yi Road, Tsing Yi Island, N.T., Hong Kong","institution_ids":["https://openalex.org/I144743875"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017439960","display_name":"Thomas Ray Einarson","orcid":"https://orcid.org/0000-0003-3865-2533","observed_orcids":["https://orcid.org/0000-0003-3865-2533"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Thomas R. Einarson","raw_affiliation_strings":["Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, M5S 3M2, Canada","institution_ids":["https://openalex.org/I185261750"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5017439960"],"corresponding_institution_ids":["https://openalex.org/I185261750"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.26780607,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":"3-4","first_page":"19","last_page":"37"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11161","display_name":"Consumer Market Behavior and Pricing","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1406","display_name":"Marketing"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/product-line-extension","display_name":"product line extension","score":0.9919999837875366},{"id":"https://openalex.org/keywords/generic-drugs","display_name":"generic drugs","score":0.8349999785423279},{"id":"https://openalex.org/keywords/brand-name-drugs","display_name":"brand-name drugs","score":0.8949999809265137},{"id":"https://openalex.org/keywords/drug-market-entry","display_name":"drug market entry","score":0.6349999904632568},{"id":"https://openalex.org/keywords/market-share","display_name":"market share","score":0.46700000762939453},{"id":"https://openalex.org/keywords/prescription-claims","display_name":"prescription claims","score":0.7160000205039978},{"id":"https://openalex.org/keywords/ciprofloxacin","display_name":"ciprofloxacin","score":0.7900000214576721},{"id":"https://openalex.org/keywords/fenofibrate","display_name":"fenofibrate","score":0.9959999918937683},{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":0.9959999918937683},{"id":"https://openalex.org/keywords/clarithromycin","display_name":"clarithromycin","score":1.0},{"id":"https://openalex.org/keywords/tolterodine","display_name":"tolterodine","score":0.949999988079071}],"concepts":[{"id":"https://openalex.org/C127576917","wikidata":"https://www.wikidata.org/wiki/Q624630","display_name":"Competitor analysis","level":2,"score":0.7577413320541382},{"id":"https://openalex.org/C2988046880","wikidata":"https://www.wikidata.org/wiki/Q3084961","display_name":"Product line","level":2,"score":0.6170201301574707},{"id":"https://openalex.org/C90673727","wikidata":"https://www.wikidata.org/wiki/Q901718","display_name":"Product (mathematics)","level":2,"score":0.5849995017051697},{"id":"https://openalex.org/C16051113","wikidata":"https://www.wikidata.org/wiki/Q828814","display_name":"Market share","level":2,"score":0.58498215675354},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.5555046796798706},{"id":"https://openalex.org/C162853370","wikidata":"https://www.wikidata.org/wiki/Q39809","display_name":"Marketing","level":1,"score":0.505160391330719},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.42777952551841736},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.17174479365348816},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.11722582578659058},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.09080898761749268},{"id":"https://openalex.org/C2524010","wikidata":"https://www.wikidata.org/wiki/Q8087","display_name":"Geometry","level":1,"score":0.0},{"id":"https://openalex.org/C117671659","wikidata":"https://www.wikidata.org/wiki/Q11049265","display_name":"Manufacturing engineering","level":1,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3109/j058v17n03_03","doi":"https://doi.org/10.3109/j058v17n03_03","is_oa":false,"landing_page_url":"https://doi.org/10.3109/j058v17n03_03","pdf_url":null,"source":{"id":"https://openalex.org/S9455094","display_name":"Journal of Pharmaceutical Marketing & Management","issn_l":"0883-7597","issn":["0883-7597","1540-8574"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320623","host_organization_name":"Haworth Press","host_organization_lineage":["https://openalex.org/P4310320623"],"host_organization_lineage_names":["Haworth Press"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmaceutical Marketing & Management","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.4000000059604645,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":4,"referenced_works":["https://openalex.org/W2054331980","https://openalex.org/W2082560103","https://openalex.org/W2110607907","https://openalex.org/W2282921829"],"related_works":["https://openalex.org/W2358804928","https://openalex.org/W4225710828","https://openalex.org/W1998528887","https://openalex.org/W2965538880","https://openalex.org/W1601893083","https://openalex.org/W2528370785","https://openalex.org/W2083314323","https://openalex.org/W4253707442","https://openalex.org/W328633100","https://openalex.org/W44205303"],"abstract_inverted_index":{"We":[0],"examined":[1],"the":[2,92,95,100],"success":[3,85],"of":[4,94],"product":[5],"line":[6],"extensions":[7],"(PLEs)":[8],"in":[9],"Canada":[10,32],"by":[11],"studying":[12],"five":[13],"selected":[14],"drugs,":[15],"three":[16],"with":[17,66],"generic":[18],"competitors":[19],"(ciprofloxacin,":[20],"fenofibrate,":[21],"paroxetine)":[22],"and":[23,45,56,88],"two":[24],"without":[25],"(clarithromycin,":[26],"tolterodine).":[27],"Third-party":[28],"prescription":[29],"claims":[30],"from":[31],"were":[33],"used":[34],"to":[35,82],"examine":[36],"market":[37,79],"behavior,":[38],"which":[39],"was":[40,61],"analyzed":[41],"using":[42],"multiple":[43],"regression":[44],"ARIMA.":[46],"Consistent":[47],"negative":[48],"associations":[49],"indicated":[50],"high":[51],"substitutability":[52],"for":[53,64],"all":[54],"products":[55],"their":[57],"generics.":[58],"However,":[59],"this":[60],"found":[62],"only":[63],"PLEs":[65,75],"distinct":[67],"advantages":[68],"(e.g.,":[69],"increased":[70],"bioavailability,":[71],"fewer":[72],"side":[73],"effects).":[74],"may":[76],"recapture":[77],"some":[78],"share":[80],"lost":[81],"generics,":[83],"but":[84],"is":[86],"product-specific":[87],"likely":[89],"depends":[90],"on":[91],"extent":[93],"PLE's":[96],"therapeutic":[97],"advantage":[98],"over":[99],"originator.":[101]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}